Funding of $25 million boosts rapid expansion of remote patient monitoring technology in France and globally

In a significant development for the healthcare industry, Resilience, a pioneering remote patient care solution in oncology, has secured a new $25M fundraising round led by Picus Capital and Red River West. This funding will accelerate Resilience's deployment in France and its international expansion, with plans to expand into Belgium, Germany, and potentially other countries.

Founded in partnership with Gustave Roussy, the leading cancer center in Europe, Resilience offers a Remote Patient Monitoring platform and mobile application designed to personalize, humanize, and enhance the care pathway for patients with cancer. The solution supports individuals affected by cancer in managing treatment-related side effects and fostering self-care.

The regulatory agency (HAS) has recognised the clinical and organisational impact of Resilience's solution, enabling it to establish itself as a new standard of care for the medical follow-up in oncology. The company's Remote Patient Care solution has already been deployed in more than 90 medical centers in France, representing over 10,000 patients.

Resilience's co-founders and co-CEOs, Céline Lazorthes and Jonathan Benhamou, aim to extend the positive impacts of remote monitoring, therapeutic education, and supportive care to a greater number of patients. The company is involved in 19 ongoing clinical studies and collaborates with academic and industrial partners.

The fundraising round also includes participation from Cathay Innovation, Singular, Seaya Ventures, and other long-standing investors. Cathay Innovation, a multistage venture capital firm with offices in Paris, Berlin, San Francisco, Shanghai, and Singapore, managing over €2.5B AUM and having invested in over 100 startups, has shown its commitment to Resilience's mission.

Resilience's Remote Patient Monitoring platform is a Class IIa medical device. The company will present several abstracts on remote monitoring, determinants of health, and digital supportive care at various congresses this year, including ASCO, EHA, BSMO, AFSOS, and MASCC.

In addition, Resilience is participating in two European projects: 'CARE1' and 'e-Quol'. The company also seeks to expand its development in Germany due to the high incidence of new cancers each year, with 500,000 new cases reported in 2021 according to the German Centre for Cancer Registry Data.

Notable partners of Resilience include the Jules Bordet Institute, CHU Saint Pierre, and Clinique Saint-Luc Bouge in Belgium, where the company's solution is already being used. In October 2023, Resilience became the first remote monitoring medical device in oncology to be reimbursed by the national social security in France.

To learn more about Resilience and its mission to revolutionise remote patient care in oncology, visit www.resilience.co or follow them on LinkedIn or Twitter @resilience_co.

Funding of $25 million boosts rapid expansion of remote patient monitoring technology in France and globally